ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BVP Bioscience Vct

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type Share ISIN Share Description
Bioscience Vct LSE:BVP London Ordinary Share GB0031256109 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Issue of Equity and Total Voting Rights

05/04/2024 12:44pm

UK Regulatory


Bioscience Vct (LSE:BVP)
Historical Stock Chart


From Apr 2024 to May 2024

Click Here for more Bioscience Vct Charts.
Issue of Equity and Total Voting Rights

Seneca Growth Capital VCT Plc (the "Company")

5 April 2024

Issue of Equity and Total Voting Rights

The Company announces that it has today allotted and issued 1,232,218 new B ordinary shares of 1p each in the Company (“B Shares”).

The shares were issued pursuant to an offer for subscription for B Shares launched on 24 August 2023 to raise, in aggregate, up to £10 million with an over-allotment facility of up to a further £10 million (before issue costs) (the "Offer").

Pursuant to the Offer, and the £808,516.25 of valid applications received since 5 December 2023 (the cut-off date for the last allotment of shares made on 6 December 2023), and up to and including 4 April 2024 in respect of the 2023/2024 tax year, the Company has today allotted and issued 1,232,218 B Shares. In accordance with the allotment formula set out in the prospectus for the Offer, the B Shares have been allotted at the offer prices in the range of 63.7p to 67.8p per share, calculated by reference to the unaudited net asset value of a B Share as at 31 March 2024 (63.7p per B Share as announced on 4 April 2024).

As a result of this allotment, the number of shares now in issue is 8,115,376 Ordinary shares of 1p each and 23,012,547 B Shares. Therefore, the total number of voting rights in the Company is 31,127,923.

In respect of this allotment, an application will be made by the Company to the Financial Conduct Authority and to the London Stock Exchange for the B Shares so issued to be admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities. It is expected that the admission of the B Shares will become effective and dealings will commence on or around 18 April 2024.

The above statement of voting capital may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Any enquiries in respect of the Offer should be directed to:
Siobhan Pycroft
Seneca Partners Limited
01942 295 981
Siobhan.Pycroft@senecapartners.co.uk


1 Year Bioscience Vct Chart

1 Year Bioscience Vct Chart

1 Month Bioscience Vct Chart

1 Month Bioscience Vct Chart

Your Recent History

Delayed Upgrade Clock